Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2011 2
2012 1
2014 1
2015 1
2016 1
2017 2
2018 3
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "DS Stage III Plasma Cell Myeloma"
Page 1
Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H. Liu F, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35545345 Free PMC article. Chinese, English.
International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, and 93 cases (17.6%) were missing. ...International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, …
International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, and 93 cases (17.6% …
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M. Szudy-Szczyrek A, et al. Cells. 2022 Feb 21;11(4):752. doi: 10.3390/cells11040752. Cells. 2022. PMID: 35203396 Free PMC article.
MiRNA-8074 is a molecule with the potential to regulate the expression of key genes related to the pathogenesis of multiple myeloma (MM), i.e., TP53, MYC, MAPK1, and KIAA. We analyzed the predictive and prognostic value of miRNA-8074 expression in MM patients. ...In …
MiRNA-8074 is a molecule with the potential to regulate the expression of key genes related to the pathogenesis of multiple myelom …
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P. Rodon P, et al. Eur J Haematol. 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. Eur J Haematol. 2001. PMID: 11168502 Review.
Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 unselected patients with MM aged 75 yr or more at diagnosis. ...Treatment toxicity was mild. Median survival was 22 months. Durie-Salmon ( …
Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 u …
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D. Xu J, et al. Cell Physiol Biochem. 2018;45(4):1631-1640. doi: 10.1159/000487730. Epub 2018 Feb 21. Cell Physiol Biochem. 2018. PMID: 29486474 Free article.
Previous studies showed high expression of CEACAM1 in multiple myeloma (MM). The aim of this study was to investigate the biological consequences of CEACAM1 overexpression in MM. ...CEACAM1 expression in patients with DS stage I was more frequent (61.5 …
Previous studies showed high expression of CEACAM1 in multiple myeloma (MM). The aim of this study was to investigate the biol …
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M. Chinen Y, et al. Cancer Res. 2014 Dec 15;74(24):7418-29. doi: 10.1158/0008-5472.CAN-14-1420. Epub 2014 Sep 30. Cancer Res. 2014. PMID: 25269480
In the clinical setting, PDPK1 was active in myeloma cells of approximately 90% of symptomatic patients at diagnosis, and the smaller population of patients with multiple myeloma exhibiting myeloma cells without active PDPK1 showed a significantly less …
In the clinical setting, PDPK1 was active in myeloma cells of approximately 90% of symptomatic patients at diagnosis, and the smaller …
The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY, Ma MC, Wang MC, Hsue SS. Lu SY, et al. J Formos Med Assoc. 2021 Nov;120(11):1967-1976. doi: 10.1016/j.jfma.2021.01.015. Epub 2021 Feb 4. J Formos Med Assoc. 2021. PMID: 33551311 Free article.
BACKGROUND/PURPOSE: Myeloma jaw lesions are not uncommon. The study aimed to investigate the status of jaw lesions and medication-related osteonecrosis of jaw (MRONJ) in multiple myeloma (MM) patients. ...RESULTS: Median age of the patients was 67.8 years, an …
BACKGROUND/PURPOSE: Myeloma jaw lesions are not uncommon. The study aimed to investigate the status of jaw lesions and medication-rel …
Association of Growth Differentiation Factor-15 Polymorphisms and Growth Differentiation Factor-15 Serum Levels with Susceptibility to Multiple Myeloma in a Chinese Population.
Li R, Hu Z, Chen H, Lu Y, Qin S, Huang C, Yao Y, Qin X, Wang C. Li R, et al. Clin Lab. 2021 Jan 1;67(1). doi: 10.7754/Clin.Lab.2020.200341. Clin Lab. 2021. PMID: 33491432
BACKGROUND: The aim of our study was to evaluate the relationship between growth differentiation factor-15 (GDF15) rs1058587, rs4808793, and rs1059369 polymorphisms, serum concentrations of GDF15, and International Staging System (ISS) staging or Durie-Salmon sta …
BACKGROUND: The aim of our study was to evaluate the relationship between growth differentiation factor-15 (GDF15) rs1058587, rs4808793, and …
The Role of (18)F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W. Deng S, et al. Contrast Media Mol Imaging. 2018 Jul 30;2018:4198673. doi: 10.1155/2018/4198673. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30154686 Free PMC article.
We aimed at comparing the Durie-Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMPeTUs) with other two staging systems in predicting prognosis of patients with all stages of newly diagnosed multiple …
We aimed at comparing the Durie-Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMP …
Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, Meng H. Qian J, et al. Hematology. 2017 Sep;22(8):472-476. doi: 10.1080/10245332.2017.1309493. Epub 2017 May 2. Hematology. 2017. PMID: 28463078
OBJECTIVE: This study aims to explore the clinical features of multiple myeloma (MM) and the influence of various prognostic factors on survival. ...IgG was the most common type (46.6%). 52.2% of the patients were diagnosed on stage IIIA according to Durie-Sa …
OBJECTIVE: This study aims to explore the clinical features of multiple myeloma (MM) and the influence of various prognostic f …
International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT. Yang SH, et al. Ann Hematol. 2012 Jan;91(1):93-102. doi: 10.1007/s00277-011-1251-y. Epub 2011 May 17. Ann Hematol. 2012. PMID: 21584671
The applicability of the International Staging System (ISS) for Chinese patients with multiple myeloma (MM) has not been demonstrated, especially with respect to treatments with novel agents. ...A total of 389 MM patients (71% male) were enrolled, with median …
The applicability of the International Staging System (ISS) for Chinese patients with multiple myeloma (MM) has not bee …
13 results